08.12.14
Irvine, Calif.-based Masimo Corp.’s noninvasive and continuous hemoglobin (SpHb) technology has been used in a study published in the journal Anesthesia and Analgesia. The technology showed a positive correlation for trending when compared with invasive lab measurements in pediatric patients undergoing surgeries with potential for substantial blood loss.
In the study, Mario Patino, M.D., and colleagues from the department of anesthesiology at Cincinnati Children’s Hospital in Ohio, assessed the trending and point accuracy of SpHb pediatric patients versus arterial blood samples analyzed on a hematology analyzer (they used Abbott Labs’ Cell-Dyn Sapphire). They also evaluated the impact of SpHb in vivo adjustment on accuracy comparisons.
In vivo adjustment, a feature currently available in select European and other non-U.S. markets, allows clinicians to adjust the SpHb measurement to that of an initial blood sample analyzed with the clinician’s invasive reference hemoglobin analyzer. This feature helps account for reference invasive instrument and individual patient variation.
SpHb was tested in 46 patients aged 2 months to 17 years. Patient selection was limited to those undergoing surgical procedures associated with substantial blood loss, such as cardiac surgery, liver/small bowel transplantation, and multilevel spine surgeries.
The authors concluded that, “noninvasive, continuous Hb monitoring by Pulse CO-Oximetry (SpHb) displayed similar trending and absolute accuracy in pediatric patients undergoing a variety of surgical procedures associated with blood loss as has been found in adult surgical patients,” adding that, “trending SpHb values has the potential to supplement detection of changes of Hb concentration by invasive blood draws.”
“This study adds to the growing body of clinical evidence supporting the value of SpHb’s use with pediatric patients,” said Stephen Barker, M.D., Ph.D., chairman of Masimo’s scientific advisory board. “As with adult patients, SpHb can help clinicians noninvasively assess hemoglobin levels and trending, which has been shown to lead to better clinical decisions and improved patient outcomes.”
In the study, Mario Patino, M.D., and colleagues from the department of anesthesiology at Cincinnati Children’s Hospital in Ohio, assessed the trending and point accuracy of SpHb pediatric patients versus arterial blood samples analyzed on a hematology analyzer (they used Abbott Labs’ Cell-Dyn Sapphire). They also evaluated the impact of SpHb in vivo adjustment on accuracy comparisons.
In vivo adjustment, a feature currently available in select European and other non-U.S. markets, allows clinicians to adjust the SpHb measurement to that of an initial blood sample analyzed with the clinician’s invasive reference hemoglobin analyzer. This feature helps account for reference invasive instrument and individual patient variation.
SpHb was tested in 46 patients aged 2 months to 17 years. Patient selection was limited to those undergoing surgical procedures associated with substantial blood loss, such as cardiac surgery, liver/small bowel transplantation, and multilevel spine surgeries.
The authors concluded that, “noninvasive, continuous Hb monitoring by Pulse CO-Oximetry (SpHb) displayed similar trending and absolute accuracy in pediatric patients undergoing a variety of surgical procedures associated with blood loss as has been found in adult surgical patients,” adding that, “trending SpHb values has the potential to supplement detection of changes of Hb concentration by invasive blood draws.”
“This study adds to the growing body of clinical evidence supporting the value of SpHb’s use with pediatric patients,” said Stephen Barker, M.D., Ph.D., chairman of Masimo’s scientific advisory board. “As with adult patients, SpHb can help clinicians noninvasively assess hemoglobin levels and trending, which has been shown to lead to better clinical decisions and improved patient outcomes.”